Cover Image

GlaxoSmithKline and developing country access to essential medicines (A) /

The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world's second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world's leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberc...

Full description

Bibliographic Details
Main Authors: Smith, N. Craig (Author), Duncan, Anne (Author)
Format: eBook
Language:English
Published: London : NeilsonJournals Publishing, 2005.
Series:SAGE Knowledge. Cases.
Subjects:
GlaxoSmithKline.
GlaxoSmithKline
Drug accessibility.
Pharmaceutical industry.
Drug Industry
Médicaments > Accessibilité.
Industrie pharmaceutique.
Drug accessibility
Pharmaceutical industry
Electronic books.
Case Reports
Case studies.
Études de cas.
Online Access:Connect to the full text of this electronic book
Description
Summary:The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world's second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world's leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures?
Item Description:Originally Published InSmith, N. C., & Duncan, A. (2005). GlaxoSmithKline and developing country access to essential medicines (A). Journal of Business Ethics Education, 2(1), 97-122. JBEE2-1CS1.
Physical Description:1 online resource : illustrations.
Bibliography:Includes bibliographical references and index.
ISBN:9781526460653
1526460653